Alyssin is a sulforaphane homolog and antioxidant. It induces phase II enzymes and increases Nrf2 levels in adenocarcinoma cells. It is has been shown to decrease the metabolism of polycyclic aromatic hydrocarbons, supressing the risk of carcinogenesis in vitro.

Alternariol is a mycotoxin, topoisomerase I and II inhibitor and potential ER agonist found in Alternaria.

Acepromazine maleate, also known as Sch-10649, is a dopamine D1/2 receptor and 5-HT1A/2A receptor antagonist used to prevent nausea and induce sedation. Acepromazine maleate is discontinued.

Pramiverin HCl is a bioactive chemical.

MS4 is a novel glucocorticoid receptor (GR) agonist with anti-inflammatory activity and displaying reduced impact on islets.

Nevirapine-d3 is deuterized nevirapine, reducing P450 metabolite formation, impacting on phase II metabolism and hepatocyte protein expression.

Garcinoic Acid is a natural and selective agonist of pregnane X receptor.

Levothyroxine sodium is a thyroid hormone.

Oxacillin (trade name Bactocill) is a narrow-spectrum beta-lactam antibiotic of the penicillin class developed by Beecham. It was patented in 1960 and approved for medical use in 1962. Oxacillin is a penicillinase-resistant β-lactam. It is similar to methicillin, and has replaced methicillin in clinical use.

Nafcillin sodium is an antibacterial chemical.

Niclosamide-olamine is a Insect Attractant, Repellent and Chemosterilant.

MRK-740 is a novel potent (IC50: 80?±?16?nM), selective and cell-active PRDM9 inhibitor, specifically and directly inhibiting H3K4 methylation at endogenous PRDM9 target loci.

NPE-caged-HPTS is a caged fluorescent pH indicator, rapidly releasing the fluorophore HPTS (pKa 7.25) upon two-photon excitation (>3000 s-1).

CRBN-6-5-5-VHL is a novel cell-permeable, potent and selective cereblon degrader.

COH34 S-dioxide is an oxidized analog of COH34

C620-0696 is a novel potent inhibitor of bromodomain PHD-finger transcription factor (BPTF).

ZK93426 is a potent, selective and competitive benzodiazepine receptor antagonist (IC50 values are 0.4 and 0.7 nM for inhibition of [3H]-flunitrazepam binding to rat cerebellum and hippocampus respectively)

ZK93423 is a potent benzodiazepine receptor agonist (IC50 = 1 nM). ZK93423 is non-selective between α1-, α2-, α3- and α5-subunit containing GABAA receptors (Ki values are 4.1, 4.2, 6 and 4.5 nM for inhibition of [3H]Ro15-1788 binding to human recombinant α1β3γ2, α2β3γ2, α3β3γ2 and α5β3γ2 receptors respectively).

YS121 is a dual inhibitor of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.

YM976 is an orally active PDE4 inhibitor (IC50 = 2.2 nM). YM976 has low emetogenic activity, suggested to be due to poor brain penetration.

XAP044 is a potent and selective mGlu7 antagonist (IC50 = 88 nM). It inhibits lateral amygdala long term potentiation (LTP) in brain slices from wild type mice. XAP044 displays no effects on the LTP of mGlu7 deficient mice.

WIN 64338 hydrochloride is a potent, non-peptide, competitive bradykinin B2 receptor antagonist.WIN 64338 inhibits [3H]-bradykinin binding on guinea pig trachea with nanomolar affinity but is not active in the rabbit aorta (the classical bradykinin B1 preparation).

WB 4101 hydrochloride is a α1A-adrenergic selective antagonist.

VU0424465 is a potent mGlu5 positive allosteric modulator and agonist

DCPIB is a novel Inhibitor of Volume-Regulated Anion Channels, Distinctly Modulating K2P Channels.

VU0285683 is a negative allosteric modulator of mGlu5 receptors. VU0285683 acts as a full antagonist and blocks the glutamate response to mGlu5 (IC50 = 24.4 nM). VU0285683 is selective for mGlu5 over mGlu1, mGlu3 and mGlu4.

VRT-532 is a CFTR modulator for the treatment of cystic fibrosis.

U69593 is a a selective KOR-1 (κ1-opioid receptor) agonist. U-69593 is known to inhibit cocaine sensitization in meso-limbic dopamine neurons by normalizing basal overflow of dopamine.

TG6-129 is an antagonist of the EP2 receptor, suppressing PGE2-induced elevation of cAMP in cells expressing EP2 with an IC50 value of 1.6 μM. It is without effect on EP4, DP1, IP, and β2-adrenergic receptors. TG6-129 reduces the expression of COX-2, IL-1β, IL-12, IL-23, IL-6, and TNF-α induced by the EP2-selective agonist butaprost in P388D1 macrophages.

SSR 146977 is a new potent nonpeptide tachykinin NK3 receptor antagonist.